- Home
- ECAT vs ARDX Comparison
ECAT vs ARDX Comparison
Compare ECAT & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ECAT | ARDX |
|---|---|---|
| Founded | 2021 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ECAT | ARDX |
|---|---|---|
| Price | $15.37 | $5.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $15.14 |
| AVG Volume (30 Days) | 488.4K | ★ 3.3M |
| Earning Date | 01-01-0001 | 04-30-2026 |
| Dividend Yield | ★ 9.20% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,607,000.00 |
| Revenue This Year | N/A | $37.75 |
| Revenue Next Year | N/A | $34.24 |
| P/E Ratio | $6.32 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.36 | $3.74 |
| 52 Week High | $17.14 | $8.40 |
Technical Indicators
Market Signals| Indicator | ECAT | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 50.17 | 40.40 |
| Support Level | $15.32 | $5.46 |
| Resistance Level | $15.77 | $6.29 |
| Average True Range (ATR) | 0.26 | 0.31 |
| MACD | -0.03 | 0.04 |
| Stochastic Oscillator | 51.56 | 8.59 |
Price Performance
Historical ComparisonAbout ECAT BlackRock ESG Capital Allocation Term Trust of Beneficial Interest
BlackRock ESG Capital Allocation Trust is a non-diversified, closed-ended management investment company. The Trust's investment objectives are to provide total return and income through a combination of current income, current gains, and long-term capital appreciation.
About ARDX Ardelyx Inc.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.